Abstract
Understanding factors that impact on the accuracy of HIV viral load (VL) results is key to quality improvements of VL programmes, particularly in resource limited settings. In this study we evaluated whether testing delay and room temperature storage (between 25-30°C) prior to testing affected results. 249 individuals who were on antiretroviral therapy, or with newly diagnosed HIV, were recruited and three PPT samples were collected from each patient. One sample was tested within 24 hours, while the others were stored un-centrifuged at ambient temperature prior to testing.
Centrifugation and testing of matched samples were performed on days 4 and 7 after collection. In samples with initial VL >2 log copies/mL, time delay and ambient temperature storage had minimal impact. When grouped according to day 1 VL range, 96-100% of samples at day 4 and 93-100% at day 7 had a VL within 0.5 log copies/mL of the first result. Greatest variability was observed at day 4 and 7 when the day 1 VL was <2 log copies/mL, however, there was no trend of increasing difference with time. Of day 1 samples with undetectable VL or VL <50copies/mL, 80% and 78% had concordant results at days 4 and 7, respectively. Detection in later samples appeared to be stochastic, rather than showing a worsening trend. These results provide further evidence that VL is stable in PPT tubes for up to 7 days when stored at room temperature. It shows that there is significant variability in samples with VL close to the limit of detection, not affected by testing delay. Stochastic variation or technical factors that may increase the chance of false positive results could possibly account for this.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work. However, laboratory testing was performed using resources of the National Health Laboratory Service, Johannesburg, South Africa
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Cape Town research ethics committee
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
file containing raw HIV viral load data has been included in supplementary data
